secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001193125-24-178809
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics FDA requires additional non-clinical data before initiating Phase 2 ALS trial for COYA 302
--------------------------------------------------------------------------------

- Submitted IND for Phase 2 double-blind, placebo-controlled study of COYA 302 in ALS on June 14, 2024.
- FDA notified on July 12, 2024 that additional non-clinical data is required prior to study initiation.
- FDA will provide details on required data within 30 days.
- Study was designed as 24-week treatment phase with 24-week open-label extension.
- Regulatory delay may push back clinical timeline for COYA 302.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524178809/0001193125-24-178809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524178809/d762748d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-178809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer